Disease Topics

Disease Topics

48 Disease areas packed with insight

Disease Topics

Knowledge Centres

Diagnosis, patient management, treatment strategies & decision support

Drug Database

Drug Database

Summary information on thousands of prescription drugs available in 9 languages

News

News

News written for doctors around pharmacological development

Treatment Guidelines

Clinical Guidelines

Professional association and governmental guidance on treatment

Disease Topics

Clinical Trials

Medical research & drug development - current and past landmark studies

Medical Journals

Medical Journals

Journal articles, titles and extracts from respected publishers

Disease Topics

Medical Apps

All the latest free and paid-for Apps selected for doctors

Welcome to epgonline.org - the website for healthcare professionals

What's new? The Type 2 Diabetes Knowledge Centre

Based on current estimates, the global prevalence of type 2 diabetes has increased almost 10 fold since 1985 and is expected to rise to 552 million by 2030,1 and when absolute numbers of people with diabetes are considered, it is South East Asia and the West Pacific that are expected to experience the highest increases in prevalence over the coming years.2

Type 2 diabetes can be defined according to fasting plasma glucose (FPG) and 2 hour plasma glucose levels. The first is assessed after 8-10 hours of fasting, usually in the morning. The second is measured by an oral glucose tolerance test (OGTT) assessing venous plasma glucose 2 hour after ingestion of a 75g oral glucose load.

Type 2 Diabetes involves two primary pathogenic mechanisms; insulin resistance and impaired insulin secretion. Insulin resistance occurs when the insulin in the body does not exert sufficient action proportional to its blood concentration.3,4 Impaired insulin secretion is characterised by decreased glucose responsiveness, and is observed before the clinical onset of disease.4

Latest News

NICE recommends Revlimid for specific Myelodysplastic syndromes- Celgene

21-Aug-2014

In new final draft guidance, the ...

Boehringer files NDA at FDA for olodaterol + tiotropium for COPD.

21-Aug-2014

Boehringer Ingelheim has announced ...

Migalastat success in Phase III (Study 012) for treatment of Fabry disease- Amicus Therapeutics

21-Aug-2014

Amicus Therapeutics announced ...

Successful Phase-III studies of CAZ AVI for Intra-Abdominal Infections-AstraZeneca + Forest

20-Aug-2014

AstraZeneca announced positive ...

US Government closes investigation into PLATO trial of Brilinta and will take no further action- AstraZeneca

20-Aug-2014

AstraZeneca announced that it has ...

Second Phase III trial of AMG 416 success for Sec. Hyperparathyroidism-Amgen

20-Aug-2014

Amgen announced that a second ...

FDA grants tentative approval for Basaglar for Types 1 and 2 Diabetes- Eli Lilly + Boehringer

20-Aug-2014

The FDA granted tentative approval ...

Recent Updates

Drugs

Clinical Guidelines

Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Neurological problems in liver transplantation

Parkinson’s disease: Diagnosis and management in primary and secondary care

Caesarean section

Medical Journals

Feeding difficulties in children with esophageal atresia: treatment by a multidisciplinary team

Using Parent Questionnaires to Assess Neurodevelopment in Former Preterm Infants: A Validation Study

A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery

Are toll-like receptors and decoy receptors involved in the immunopathogenesis of systemic lupus erythematosus and lupus-like syndromes?

epgonline.org Social